A Study to Evaluate the Efficacy, Safety and Immunogenicity of MTBVAC in Adolescents and Adults Living in a TB Endemic Region.
A Phase 2b, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Efficacy, Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine, MTBVAC, Against TB Disease in Adolescents and Adults Aged 14-45 Years, Living in a TB Endemic Region.
Sponsor: Biofabri, SLU
A PHASE2 clinical study on Tuberculosis (TB), this trial is actively recruiting participants. The trial is conducted by Biofabri, SLU and has accumulated 5 data snapshots since 2025. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
5 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Oct 2025 — Mar 2026 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Oct 2025 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Not Yet Recruiting PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biofabri, SLU
- International AIDS Vaccine Initiative
- Universidad de Zaragoza
For direct contact, visit the study record on ClinicalTrials.gov .